Drug Trial Radar · NCT06307925
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
122
Planned (sponsor's estimate)
Start
Mar 27, 2024
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- HC Biopharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a multicenter, open, single-arm, non-randomized, dose-escalation and dose-expansion, phase I clinical study in patients with advanced recurrent or metastatic solid tumors.The goal of this study is to evaluate the safety and tolerability of HC010 monotherapy in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
HC010Drug
HC010 Q2W/28d intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicityTime frame: 28 days
- Adverse eventsTime frame: 2 years
- serious adverse eventsTime frame: 2 years
- Maximum Tolerated DoseTime frame: 2 years
- Recommended Dose for Phase II Clinical StudiesTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.